We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

152 hedge funds and large institutions have $329M invested in PDL BioPharma, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

476% more call options, than puts

Call options by funds: $334K | Put options by funds: $58K

10% more capital invested

Capital invested by funds: $298M → $329M (+$31.2M)

7% less funds holding

Funds holding: 163 → 152 (-11)

30% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 56

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

Holders
152
Holders Change
-11
Holders Change %
-6.75%
% of All Funds
3.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
39
Reduced
56
Closed
25
Calls
$334K
Puts
$58K
Net Calls
+$276K
Net Calls Change
+$359K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
+$13.1M
2
BIP
Brandes Investment Partners
California
+$8.99M
3
AC
Armistice Capital
New York
+$4.42M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.19M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.09M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$6.65M
2
BlackRock
BlackRock
New York
-$3.69M
3
AQR Capital Management
AQR Capital Management
Connecticut
-$3.43M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.17M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.95M

PDLI Hedge Fund Activity: Q3 2018 in Review

152 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2018, worth a combined $329M — up 10% from $298M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PDLI and 15 opened new positions — a net loss of 10 holders — while 56 trimmed existing stakes and 39 added.

The largest buyer was Kennedy Capital Management, adding an estimated $13.1M. The largest seller was Vanguard Group, cutting an estimated $6.65M.

  • 152 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2018, down from 163 in Q2 2018.
  • Funds reported $329M of PDL BioPharma, Inc. stock for Q3 2018, up 10% quarter-over-quarter.
  • 15 funds opened new PDL BioPharma, Inc. positions in Q3 2018 and 25 closed out, a net change of -10 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2018 was Kennedy Capital Management, an estimated $13.1M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2018 was Vanguard Group, an estimated $6.65M sold.

Based on aggregated 13F filings for Q3 2018.